Regulation of the androgen receptor by post-translational modifications
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The androgen receptor (AR) is a key molecule in prostate cancer and Kennedy's disease. Understanding the regulatory mechanisms of this steroid receptor is important in the development of potential therapies for these diseases. One layer of AR regulation is provided by post-translational modifications including phosphorylation, acetylation, sumoylation, ubiquitination and methylation. While these modifications have mostly been studied as individual events, it is becoming clear that these modifications can functionally interact with each other in a signalling pathway. In this review, the effects of all modifications are described with a focus on interplay between them and the functional consequences for the AR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Phosphorylation and activation of androgen receptor by Aurora-A.
Shu, S.-K., Liu, Q., Coppola, D., & Cheng, J. Q. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121129 · Cited by 38 · cited 1×
“For example, Ser292 can be phosphorylated by Aurora A kinase, which is frequently overexpressed in numerous cancers, including PC, to promote cell survival, phosphorylation-dependent transactivation and PSA induction in the presence or absence of androgens (Shu et al. 2010).”
BackgroundRetractedActivation of the human androgen receptor through a protein kinase A signaling pathway.
Nazareth, L. V., & Weigel, N. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.33.19900 · Cited by 429 · cited 1×
“In the absence of androgens, PKA activates the AR (Gioeli et al. 2002), an effect Journal of Endocrinology (2012) 215, 221–237 that can be inhibited by bicalutamide and flutamide and is believed to be a consequence of increased nuclear AR levels (Nazareth & Weigel 1996).”
BackgroundAkt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
Zhao, Y., Lang, G., Ito, S., Bonnet, J., Metzger, E., Sawatsubashi, S., Suzuki, E., Le Guezennec, X., Stunnenberg, H. G., Krasnov, A., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.011 · Cited by 382
Regulation of androgen receptor activity by tyrosine phosphorylation.
Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., Nesheiwat, I., Kong, X., Melamed, J., Handratta, V. D., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.021 · Cited by 364 · cited 6×
“Furthermore, Tyr534-mutant AR is not stimulated to translocate to the nucleus by Src activation (Guo et al. 2006).”
BackgroundMethodInfluentialUeda, T., Mawji, N. R., Bruchovsky, N., & Sadar, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203313200 · Cited by 311 · cited 9×
“Furthermore, Tyr534-mutant AR is not stimulated to translocate to the nucleus by Src activation (Guo et al. 2006).”
BackgroundInfluentialMahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., & Whang, Y. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700420104 · Cited by 274 · cited 1×
“Tyr267 appears to be the dominant functional site as mutation studies demonstrated that, whereas mutation of Tyr363 can inhibit AR activity, mutation of Tyr267 completely abolished HRG-stimulated AR activation (Mahajan et al. 2007).”
BackgroundHaelens, A., Tanner, T., Denayer, S., Callewaert, L., & Claessens, F. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1701 · Cited by 153
Regulation of the androgen receptor by SET9-mediated methylation.
Gaughan, L., Stockley, J., Wang, N., McCracken, S. R. C., Treumann, A., Armstrong, K., Shaheen, F., Watt, K., McEwan, I. J., Wang, C., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq861 · Cited by 127 · cited 1×
“Furthermore, many lysine demethylases (KDMs) and methyltransferases (KMTs) have been detailed as nuclear receptor coregulator proteins with direct AR-Me being documented in 2011 by Gaughan et al. (2011), which was quickly followed by a second report by Ko et al. (2011).”
BackgroundSelf-citationAi, J., Wang, Y., Dar, J. A., Liu, J., Liu, L., Nelson, J. B., & Wang, Z. (2009) · Molecular Endocrinology · doi:10.1210/me.2009-0188 · Cited by 126 · cited 1×
“Another example is HSP90-Ac, which results in destabilisation of the AR leading to its destruction by the proteasome (Ai et al. 2009, Gibbs et al. 2009).”
BackgroundKraus, S., Gioeli, D., Vomastek, T., Gordon, V., & Weber, M. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0596 · Cited by 118
Liu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H. S., & Whang, Y. E. (2010) · Oncogene · doi:10.1038/onc.2010.103 · Cited by 106
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Mahajan, K., Challa, S., Coppola, D., Lawrence, H., Luo, Y., Gevariya, H., Zhu, W., Chen, Y. A., Lawrence, N. J., & Mahajan, N. P. (2010) · The Prostate · doi:10.1002/pros.21163 · Cited by 86
Salas, T. R., Kim, J., Vakar-Lopez, F., Sabichi, A. L., Troncoso, P., Jenster, G., Kikuchi, A., Chen, S.-Y., Shemshedini, L., Suraokar, M., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309560200 · Cited by 81
Inhibition of androgen receptor activity by histone deacetylase 4 through receptor SUMOylation
Yang, Y., Tse, A. K.-W., Li, P., Ma, Q., Xiang, S., Nicosia, S. V., Seto, E., Zhang, X., & Bai, W. (2011) · Oncogene · doi:10.1038/onc.2010.600 · Cited by 72
Yang, C.-S., Xin, H.-W., Kelley, J. B., Spencer, A., Brautigan, D. L., & Paschal, B. M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02411-06 · Cited by 55 · cited 1×
“…only two protein phosphatases have been described to interact with and dephosphorylate the AR. Protein phosphatase 2A (PP2A) was the first enzyme to be identified to bind to ligand-activated AR and result in dephosphorylation at multiple sites (Table 3; Lin et al. 2002, Yang et al. 2005, 2007).”
BackgroundKesler, C. T., Gioeli, D., Conaway, M. R., Weber, M. J., & Paschal, B. M. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0240 · Cited by 35 · cited 5×
“Ser81 phosphorylation occurs in the nucleus, similar to Ser256 and Ser308 (Kesler et al. 2007), w4 h post-androgen stimulation, suggesting that this residue is not responsible for enhancing nuclear translocation or DNA binding; hence, rapidly induced genes do not require this phosphorylation event…”
BackgroundInfluential
Cited by
USP22 regulates oncogenic signaling pathways to drive lethal cancer progression
Schrecengost, R. S., Dean, J. L., Goodwin, J. F., Schiewer, M. J., Urban, M. W., Stanek, T. J., Sussman, R. T., Hicks, J. L., Birbe, R. C., Draganova-Tacheva, R. A., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1954 · Cited by 126
“The androgen receptor ligand-binding domain contains 2 lysine residues (845 and 847) that promote degradation upon ubiquitylation, suggesting that regulation of AR-SV expression is independent of these canonical proteasomal degradation targets (50).”
McClinch, K., Avelar, R. A., Callejas, D., Izadmehr, S., Wiredja, D., Perl, A., Sangodkar, J., Kastrinsky, D. B., Schlatzer, D., Cooper, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0123 · Cited by 78
“AR is regulated at multiple levels, with numerous post-translational modifications (PTM) including phosphorylation, acetylation, sumoylation, ubiquitination, and methylation (35, 36) with AR phosphorylation occupying a predominant role (37).”
BackgroundEvidence of androgen action in endometrial and ovarian cancers
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0551 · Cited by 73
“…q 2014 Society for Endocrinology DOI: 10.1530/ERC-13-0551 Printed in Great Britain AR is the target of several post-translational modifications including acetylation, phosphorylation, methylation, ubiquitination and sumoylation (reviewed in Coffey & Robson (2012)).”
BackgroundInfluentialYang, C.-S., Jividen, K., Kamata, T., Dworak, N., Oostdyk, L., Remlein, B., Pourfarjam, Y., Kim, I.-K., Du, K.-P., Abbas, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23055-6 · Cited by 44
Casein Kinase 1α—A Target for Prostate Cancer Therapy?
Lishman-Walker, E., & Coffey, K. (2024) · Cancers · doi:10.3390/cancers16132436 · Cited by 4
“Deregulation of the proteins responsible for these modifications can result in aberrant AR activity [4].”
BackgroundSelf-citation
Metadata
- Authors
- Coffey, K., & Robson, C. N.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2012-08-07
- Volume
- 215
- Issue
- 2
- Pages
- 221-237
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2103545212
- Cited by
- 135
- References
- 17
- FWCI
- 9.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.